For adults and children with hemophilia B

LONG-LASTING BLEED PROTECTIONFOR THE WORKHORSE WITHIN

#1 FACTOR IX MOST PRESCRIBED FOR PROPHYLAXIS*

   ONLY IDELVION DELIVERS  

Zero spontaneous bleeds

Zero median annualized spontaneous bleeding rate in adults when dosed at 7 or 14 days in phase III pivotal trials

EXPLORE IDELVION
EFFICACY
plus
Up to 14-day dosing

Individualized dosing schedule that meets your patients' needs

VIEW FULL
DOSING INFORMATION
plus
20% though levels with prophylactic use

High and sustained Factor IX levels in clinical trials

DISCOVER HIGH FACTOR IX LEVELS

*In patients 12 years and older on a weekly dose of ≤40 IU/kg for 1 month while not requiring dose adjustments or experiencing spontaneous bleeding.

†The mean dose for patients receiving prophylaxis every 7 days was 37 IU/kg.

Join us for a live webcast event!

Join us for an engaging discussion with a leading hematologist about the treatment of hemophilia B, an actual patient case study, and a clinical overview of IDELVION.

June 9
12 PM EST
With Dr. Shveta Gupta
June 22
12 PM EST
With Dr. Vinod Balasa
July 28
12:00 PM EST
With Dr. Mark Reding

Print the enrollment form

So your patients can see if it’s right for them

Resources for your patients

CSL Behring is committed to providing treatments and support services that make a meaningful difference in the lives of people with bleeding disorders.

Resources are available to help your patients get the treatment they need for hemophilia B, including:

  • A free trial of IDELVION
  • Co-pay assistance for eligible patients for up to $12,000 of annual out-of-pocket expenses
  • Lapse-in-coverage support with the CSL Behring AssuranceSM program
  • Reimbursement and access support

References: 1. Hemophilia FIX Market Assessment, Third-Party Market Research. 2. Gill JC, Roberts J, Li Y, Castaman G. Sustained high trough factor IX activity levels with continued use of rIX-FP in adult and paediatric patients with haemophilia B. Haemophilia. 2019. doi:10.1111/hae.13735.

X
You are now leaving the current website.

Do you want to continue?